News
![Concert_Pharma_logo](https://pharmaphorum.com/wp-content/uploads/2021/05/Concert_Pharma_logo.png)
Chasing Lilly, Concert eyes 2023 filing for its JAK drug for...
Concert Pharmaceuticals has started the second of two planned phase 3 trials of its drug candidate for alopecia areata (AA), a common cause of hair loss, and says it hopes to report results